Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis
10.3969/j.issn.1003-4706.2018.08.011
- VernacularTitle:200例肺腺癌脑转移患者驱动基因突变情况及预后关系
- Author:
Zhong-Shan ZHU
1
;
Wen-Hui YAN
;
Xiao-Bing LI
;
Zhou YANG
;
Peng BAI
Author Information
1. 湖南省第二人民医院肿瘤科
- Keywords:
Pulmonary adenocarcinoma;
Brain metastasis;
Targeted therapy;
Driver gene
- From:Journal of Kunming Medical University
2018;39(8):47-50
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between the driver genes mutation and the survival in patients with pulmonary adenocarcinoma brain metastasis. Methods We enrolled 200 patients with pulmonary adenocarcinoma brain metastasis confirmed histologically from Jan 2013 to Dec 2015, and tested EGFR, KRAS, ALK, Her-2 gene mutation, analyzed the relationship between EGFR gene mutation and clinicopathological data and prognosis of the patients.Results The mutation rates of EGFR, KRAS, ALK and Her-2 gene mutation were 48.5％, 5.5％, 6.5％, 3.5％, respectively. Compared with EGFR gene mutation patients, the sex, age, BMI, differentiation were significant different (P＜0.05), however, the smoking was not significant different (P＞0.05). Patients with EGFR gene mutation who received targeted therapy survived longer than who did not receive targeted therapy, (28.0 ±4.5) months vs (11.2 ±1.4) months. By Log Rank (Mantel-Cox), the median survival time between the two groups was statistically significant (P＜0.05).Conclusions The mutation rate of EGFR gene mutation was high in patients with pulmonary adenocarcinoma brain metastasis, and the patients will survivel longer by targeted therapy.
